ASSESSING THE POTENTIAL OF HYPOXIA-TARGETING AGENTS AS GSTP1 INHIBITORS IN OVERCOMING CANCER DRUG RESISTANCE
Bozok Tıp Dergisi · 15.06.2025 · 15 (2) · 178-185
DOI: 10.16919/bozoktip.1603238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bozok Tıp Dergisi, online erschienen am 15.06.2025. Verfasst von Mehmet Özcan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
The persistent challenge of drug resistance in cancer therapy is closely linked to the detoxification activity of glutathione S-transferase pi (GSTP1). This study aims to assess the potential of hypoxia-targeting agents as GSTP1 inhibitors to address drug resistance mechanisms in cancer. Materials and Methods: Molecular docking simulations were performed using the crystal structure of GSTP1 (PDB ID: 2GSS). Eight hypoxia-targeting agents were tested, including BAY 87-2243, Vadimezan, SLC-0111, Acriflavine, PX-478, Evofosfamide, Bevacizumab, and the reference GSTP1 inhibitor ethacrynic acid. Binding affinities were calculated using AutoDock Vina, and interaction profiles were visualized with Discovery Studio.
Results
Among the tested compounds, BAY 87-2243 exhibited the highest binding affinity to GSTP1 with a binding energy of -9.1 kcal/mol, surpassing ethacrynic acid (-6.7 kcal/mol). Vadimezan (-7.9 kcal/mol) and SLC-0111 (-7.2 kcal/mol) also demonstrated strong inhibitory potential. Key interactions included hydrogen bonds with residues GLN A:51 and ARG A:13 and hydrophobic interactions with PHE A:8. Other compounds displayed lower binding affinities, ranging from -6.6 to -5.7 kcal/mol.
Conclusion
Hypoxia-targeting agents, particularly BAY 87-2243, Vadimezan, and SLC-0111, show promising GSTP1 inhibition potential, offering dual functionality to modulate tumor hypoxia and counteract drug resistance. These findings warrant further in vitro and in vivo studies to explore their clinical application in cancer therapy.
Zitieren
APA
Özcan, M., & Ercan, M. (2025). ASSESSING THE POTENTIAL OF HYPOXIA-TARGETING AGENTS AS GSTP1 INHIBITORS IN OVERCOMING CANCER DRUG RESISTANCE. Bozok Tıp Dergisi, 15(2), 178-185. https://doi.org/10.16919/bozoktip.1603238
Vancouver
Özcan M, Ercan M. ASSESSING THE POTENTIAL OF HYPOXIA-TARGETING AGENTS AS GSTP1 INHIBITORS IN OVERCOMING CANCER DRUG RESISTANCE. Bozok Tıp Dergisi. 2025;15(2):178-185. doi:10.16919/bozoktip.1603238
BibTeX
@article{zcan2025,
author = {Özcan, Mehmet and Ercan, Müjgan},
title = {ASSESSING THE POTENTIAL OF HYPOXIA-TARGETING AGENTS AS GSTP1 INHIBITORS IN OVERCOMING CANCER DRUG RESISTANCE},
journal = {Bozok Tıp Dergisi},
year = {2025},
volume = {15},
number = {2},
pages = {178--185},
doi = {10.16919/bozoktip.1603238}
}
EUVIMED